Metastatic Melanoma Stage IV Clinical Trial
Official title:
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
| Verified date | April 2022 |
| Source | Philogen S.p.A. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
A prospective, open-label, multi-center, Phase I/II study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
| Status | Active, not recruiting |
| Enrollment | 96 |
| Est. completion date | June 2022 |
| Est. primary completion date | May 17, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility | Inclusion Criteria: 1. 18-70 years of age, inclusive 2. Must have histologically or cytologically confirmed cutaneous metastatic melanoma (Stage IV). For the Phase II part only patients with Stage IV M1a or M1b will be enrolled. 3. Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as identified by CT or MRI scan within 28 days before the first study drug administration. 4. Baseline LDH within normal range 5. Maximal 1 line of previous systemic treatment for metastatic disease (prior adjuvant melanoma therapy, e.g., IFN, is permitted. 6. For women of childbearing potential, a negative pregnancy test within 72 hours prior to the first dose of study treatment. 7. Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 12 weeks after the last dose of study medication. 8. Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 12 weeks after the last dose of study medication. 9. Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 10. Life expectancy of at least three months 11. Adequate organ function: serum creatinine = 1.5 x ULN, total bilirubin = 30 mM/L (or mg/dL, = 2.0 mg/dL), hepatic transaminases = 2.5 x ULN, alkaline phosphatase = 2.5 x ULN. 12. ANC count = 1.5 x 10^9/L, platelet count = 100 x 10^9/L, hemoglobin > 9 g/dL 13. Normal 12-lead ECG and normal bidimensional echocardiogram or MUGA 14. All toxic effects of prior therapy must have resolved to grade =1 unless otherwise specified above 15. Willing and able to give written informed consent. Exclusion Criteria: 1. Pregnant or breastfeeding female 2. Primary ocular melanoma 3. Primary mucosal melanoma 4. Use of any investigational or other anti-cancer drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of DTIC and L19-IL2 5. Prior radiation to a target lesion, unless there has been clear progression of the lesion since radiotherapy 6. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection 7. History or clinical evidence of brain metastases or leptomeningeal disease 8. Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix 9. Treatment with DTIC within 6 months before start of study 10. Treatment with Ipilimumab within 6 months before start of study 11. Hypersensitivity to DTIC 12. Concomitant use of drugs known to alter cardiac conduction 13. Chronic use of corticosteroids used in the management of cancer or non-cancer-related illness 14. Unstable or serious concurrent uncontrolled medical conditions 15. Inadequately controlled cardiac arrhythmias including atrial fibrillation 16. History of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris 17. Heart insufficiency > grade II NYHA criteria 18. Uncontrolled hypertension 19. Ischemic peripheral vascular disease 20. Active infection or incomplete wound healing. 21. History or evidence of active autoimmune disease. 22. Known history of allergy to intravenously administered proteins/peptides/antibodies 23. History of organ allograft.or allogeneic peripheral blood progenitor cell or bone marrow transplantation 24. Major trauma including surgery within 4 weeks prior to entering the study. 25. Any underlying medical or psychiatric condition which in the opinion of the investigator will make administration of study drug hazardous or hinder the interpretation of study results (e.g. AE). 26. Melanoma patients with BRAF 600 E mutation who are amenable to receive approved treatments able to extend overall survival. |
| Country | Name | City | State |
|---|---|---|---|
| Germany | University Hospital | Tuebingen | |
| Italy | Azienda Ospedaliera Universitaria Senese | Siena |
| Lead Sponsor | Collaborator |
|---|---|
| Philogen S.p.A. |
Germany, Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Phase I: maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2 | Establish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study | From day 1 to day 21 of Cycle 1 (each cycle is 21-days) | |
| Primary | Phase II: best objective response rate (BORR) | Evaluation of antitumor activity | Up to 1 year | |
| Secondary | Phase I: best objective response rate (BORR) | Evaluation of antitumor activity | Up to 1 year | |
| Secondary | Phase I: duration of objective response | Evaluation of the antitumor activity | From week 6 up to 1 year | |
| Secondary | Phase I: disease control rate | Evaluation of the antitumor activity | At 6 months | |
| Secondary | Phase I: median progression free survival (mPFS) | Evaluation of the antitumor activity | Up to 1 year | |
| Secondary | Phase I: median overall survival and overall survival rate | Evaluation of the antitumor activity | Up to 1 year | |
| Secondary | Phase II: safety and tolerability of L19-IL2 in combination with DTIC vs DTIC alone. | Safety evaluation including AEs, SAE and standard laboratory assessment | Up to 1 year | |
| Secondary | Phase II: duration of objective response | Up to 1 year | ||
| Secondary | Phase II: disease control rate | At 6 months | ||
| Secondary | Phase II: median progression free survival (mPFS) | Up to 1 year | ||
| Secondary | Phase II: median overall survival and overall survival rate | Up to 1 year |